Meeting
2020 ASCO Virtual Scientific Program
Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Authors
Mario Campone
Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France
Mario Campone , Christina Isabella Herold , Qiuyan Wang , Vasiliki Pelekanou , Sylvaine Cartot-Cotton , Bethany Ling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04191382
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS1108)
DOI
10.1200/JCO.2020.38.15_suppl.TPS1108
Abstract #
TPS1108
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
First Author: Yeon Hee Park
Poster
2021 ASCO Annual Meeting
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
First Author: Sarat Chandarlapaty
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
First Author: Sara M. Tolaney